Agios Pharmaceuticals, Inc. (AGIO)
收市後：
| 前收市價 | 30.21 |
| 開市 | 30.40 |
| 買盤 | 31.69 x 100 |
| 賣出價 | 32.02 x 100 |
| 今日波幅 | 30.40 - 33.02 |
| 52 週波幅 | 19.80 - 35.50 |
| 成交量 | |
| 平均成交量 | 752,112 |
| 市值 | 1.788B |
| Beta 值 (5 年，每月) | 0.86 |
| 市盈率 (最近 12 個月) | 無 |
| 每股盈利 (最近 12 個月) | -6.33 |
| 業績公佈日 | 2024年5月02日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 42.80 |
InvestorPlaceThe 3 Best Biotech Stocks to Buy Now: Q2 Edition
Some of the hottest opportunities can be found in biotech stocks to buy now. With innovation, mergers and acquisitions, major companies looking to replenish their pipelines ahead of patent expirations, treatments for obesity, aging baby boomers, and demand for better care are creating massive opportunities. We’re even seeing big opportunities in cancer treatments known as ADCs (antibody-drug conjugates), and in gene-editing. We can even look at the impact artificial intelligence could have on he
Investor's Business DailyAgios Pharmaceuticals Stock Earns IBD Stock Upgrade Again, Hitting 90-Plus RS Rating
Agios Pharmaceuticals stock had its Relative Strength (RS) Rating upgraded from 84 to 91 Monday. When looking for the best stocks to buy and watch, keep a close on eye on relative price strength. Is Agios Pharmaceuticals Stock A Buy?
Investor's Business DailyAgios Pharmaceuticals Stock Earns RS Rating Upgrade; Hits Key Benchmark
Agios Pharmaceuticals shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 65 to 84.
